Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1) insights for the functional variability across bone morphogenetic protein (BMP) antagonists

Journal of Biological Chemistry

Volumn 290, Issue 8, 2015, Pages 4759-4771

  Nolan, Kristof ^a   Kattamuri, Chandramohan ^a   Luedeke, David M ^a   Angerman, Elizabeth B ^a   Rankin, Scott A ^b   Stevens, Mariana L ^b   Zorn, Aaron M ^b   Thompson, Thomas B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CRYSTALLOGRAPHY; PROTEINS;

BINDING EPITOPES; BONE MORPHOGENETIC PROTEINS; NEUROBLASTOMAS; TUMORIGENICITY;

X RAY CRYSTALLOGRAPHY;

BONE MORPHOGENETIC PROTEIN; EPITOPE; PEPTIDES AND PROTEINS; PROTEIN NBL1; UNCLASSIFIED DRUG; BMP2 PROTEIN, HUMAN; BMP7 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; GREM2 PROTEIN, HUMAN; NBL1 PROTEIN, HUMAN; OSTEOGENIC PROTEIN 1; PROTEIN; SIGNAL PEPTIDE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; EMBRYO; IN VIVO STUDY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; XENOPUS; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHO CELL LINE; CRICETULUS; GENETICS; HAMSTER; HUMAN; MISSENSE MUTATION; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTAGENESIS; MUTATION, MISSENSE; PROTEIN STRUCTURE, TERTIARY; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84929121478     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.628412     Document Type: Article

References (41)

1. Bragdon, B., Moseychuk, O., Saldanha, S., King, D., Julian, J., and Nohe, A. (2011) Bone morphogenetic proteins: a critical review. Cell Signal. 23, 609-620
2. Cai, J., Pardali, E., Sánchez-Duffhues, G., and ten Dijke, P. (2012) BMP signaling in vascular diseases. FEBS Lett. 586, 1993-2002
3. Walsh, D. W., Godson, C., Brazil, D. P., and Martin, F. (2010) Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol. 20, 244-256
4. Rider, C. C., and Mulloy, B. (2010) Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem. J. 429, 1-12
5. Tardif, G., Pelletier, J.-P., Boileau, C., and Martel-Pelletier, J. (2009) The BMP antagonists Follistatin and Gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study. Osteoarthr. Cartil. 17, 263-270
6. Gao, H., Chakraborty, G., Lee-Lim, A. P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A. H., and Giancotti, F. G. (2012) The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764-779
7. Tamminen, J.A., Parviainen, V., Rönty, M., and Wohl, A. P. (2013) Gremlin-1 associates with Fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis 10.1038/oncsis.2013.29
8. Zhang, Y., and Zhang, Q. (2009) Bone morphogenetic protein-7 and Gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem. Biophys. Res. Commun. 383, 1-3
9. Yanagita, M. (2012) Inhibitors/antagonists of TGF-β system in kidney fibrosis. Nephrol. Dial. Transplant. 27, 3686-3691
10. Wakefield, L. M., and Hill, C. S. (2013) Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 13, 328-341
11. Cahill, E., Costello, C.M., Rowan, S. C., Harkin, S., Howell, K., Leonard, M.O., Southwood, M., Cummins, E. P., Fitzpatrick, S. F., Taylor, C. T., Morrell, N. W., Martin, F., and McLoughlin, P. (2012) Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 125, 920-930
12. Nolan, K., and Thompson, T. B. (2014) The DAN family: modulators of TGF-β signaling and beyond. Protein Sci. 23, 999-1012
13. Thompson, T. B., Lerch, T. F., Cook, R.W., and Woodruff, T. K. (2005) The structure of the Follistatin: activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell 9, 535-543
14. Groppe, J., Greenwald, J., Wiater, E., Rodriguez-Leon, J., Economides, A. N., Kwiatkowski, W., Affolter, M., Vale, W. W., Izpisua Belmonte, J.C., and Choe, S. (2002) Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420, 636-642
15. Zhang, J.-L., Qiu, L.-Y., Kotzsch, A., Weidauer, S., Patterson, L., Hammerschmidt, M., Sebald, W., and Mueller, T. D. (2008) Crystal structure analysis reveals how the Chordin family member Crossveinless-2 blocks BMP-2 receptor binding. Dev. Cell. 14, 739-750
16. Nolan, K., Kattamuri, C., Luedeke, D.M., Deng, X., Jagpal, A., Zhang, F., Linhardt, R.J., Kenny, A. P., Zorn, A.M., and Thompson, T. B. (2013) Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 21, 1417-1429
17. Veverka, V., Henry, A.J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L., Gong, J., Qian, X., Paszty, C., Taylor, R.J., Robinson, M. K., and Carr, M.D. (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890-10900
18. Weidauer, S.E., Schmieder, P., Beerbaum, M., Schmitz, W., Oschkinat, H., and Mueller, T. D. (2009) NMR structure of the Wnt modulator protein Sclerostin. Biochem. Biophys. Res. Commun. 380, 160-165
19. van Bezooijen, R. L., Svensson, J.P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P.H., Vrieling, H., Papapoulos, S.E., ten Dijke, P., and Löwik, C. W. (2007) Wnt but not BMP signaling is involved in the inhibitory action of Sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 22, 19-28
20. van Bezooijen, R. L., ten Dijke, P., Papapoulos, S.E., and Löwik, C. W. (2005) SOST/Sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16, 319-327
21. Semënov, M., Tamai, K., and He, X. (2005) SOST is a ligand for LRP5/ LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770-26775
22. Ahn, Y., Sanderson, B. W., Klein, O. D., and Krumlauf, R. (2010) Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning. Development 137, 3221-3231
23. Lintern, K. B., Guidato, S., Rowe, A., Saldanha, J. W., and Itasaki, N. (2009) Characterization of Wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 284, 23159-23168
24. Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., Huang, O. W., Gong, Y., Estevez, A., and Zilberleyb, I. (2011) Wnt antagonists bind through a short peptide to the first α-propeller domain of LRP5/6. Structure 19, 1433-1442
25. Kattamuri, C., Luedeke, D.M., Nolan, K., Rankin, S.A., Greis, K. D., Zorn, A.M., and Thompson, T. B. (2012) Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers. J. Mol. Biol. 424, 313-327
26. Ozaki, T., and Sakiyama, S. (1994) Tumor-suppressive activity of N03 gene product in v-src-transformed rat 3Y1 fibroblasts. Cancer Res. 54, 646-648
27. Ozaki, T., Enomoto, H., Nakamura, Y., Kondo, K., Seki, N., Ohira, M., Nomura, N., Ohki, M., Nakagawara, A., and Sakiyama, S. (1997) The genomic analysis of human DAN gene. DNA Cell Biol. 16, 1031-1039
28. Ozaki, T., Nakamura, Y., Enomoto, H., Hirose, M., and Sakiyama, S. (1995) Overexpression of DAN gene product in normal rat fibroblasts causes a retardation of the entry into the S phase. Cancer Res. 55, 895-900
29. Dionne, M.S., Skarnes, W. C., and Harland, R.M. (2001) Mutation and analysis of dan, the founding member of the DAN family of transforming growth factor β antagonists. Mol. Cell Biol. 21, 636-643
30. Pearce, J.J., Penny, G., and Rossant, J. (1999) A mouse Cerberus/Danrelated gene family. Dev. Biol. 209, 98-110
31. Hung, W. T., Wu, F.J., Wang, C.J., and Luo, C. W. (2012) Dan (NBL1) specifically antagonizes BMP2 and BMP4 and modulates the actions of GDF9, BMP2, and BMP4 in the rat ovary 1. Biol. Reprod. 86, 158
32. Eimon, P. M., and Harland, R.M. (2001) Xenopus Dan, a member of the Dan gene family of BMP antagonists, is expressed in derivatives of the cranial and trunk neural crest. Mech. Dev. 107, 187-189
33. Ohtori, S., Yamamoto, T., Ino, H., Hanaoka, E., Shinbo, J., Ozaki, T., Takada, N., Nakamura, Y., Chiba, T., and Nakagawara, A. (2002) Differential screening-selected gene aberrative in neuroblastoma protein modulates inflammatory pain in the spinal dorsal horn. Neuroscience 110, 579-586
34. Kim, A. S., and Pleasure, S.J. (2003) Expression of theBMPantagonist Dan during murine forebrain development. Brain Res. Dev. Brain Res. 145, 159-162
35. Tanwar, V., Bylund, J. B., Hu, J., Yan, J., and Walthall, J.M. (2014) Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. Stem Cells 32, 1774-1788
36. Kattamuri, C., Luedeke, D.M., and Thompson, T. B. (2012) Expression and purification of recombinant protein related to Dan and Cerberus (PRDC). Protein Expr. Purif. 82, 389-395
37. Sive, H. L., Grainger, R.M., and Harland, R.M. (2000) Early Development of Xenopus laevis, 1st Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
38. Avsian-Kretchmer, O., and Hsueh, A.J. (2004) Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol. Endocrinol. 18, 1-12
39. De Robertis, E.M., and Kuroda, H. (2004) Dorsal-ventral patterning and neural induction in Xenopus embryos. Annu. Rev. Cell Dev. Biol. 20, 285-308
40. Kondo, K., Ozaki, T., Nakamura, Y., and Sakiyama, S. (1995) DAN gene product has an affinity for Ni2. Biochem. Biophys. Res. Commun. 216, 209-215
41. Sidis, Y., Schneyer, A. L., and Keutmann, H. T. (2005) Heparin and activinbinding determinants in Follistatin and FSTL3. Endocrinology 146, 130-136